Enfortumab vedotin-ejfv is a type of targeted therapy called an antibody-drug conjugate. It is made of a monoclonal antibody chemically linked to a cancer-killing drug. The monoclonal antibody binds to a protein on the surface of some cancer cells. The linked drug enters these cancer cells and kills them. Enfortumab vedotin-ejfv may also stimulate the immune system to kill cancer cells.
Use in Cancer
Enfortumab vedotin-ejfv is approved to treat:
- Urothelial cancer (a type of cancer in the bladder or urinary tract) that has spread. It is used:
- Alone in adults whose cancer cannot be removed by surgery and who have received platinum chemotherapy and immunotherapy.
- Alone in adults whose cancer cannot be removed by surgery and who have received at least one other type of treatment and cannot receive cisplatin.
- With pembrolizumab in adults who cannot receive cisplatin.¹
Enfortumab vedotin-ejfv is also being studied in the treatment of other types of cancer.
More About Enfortumab Vedotin-ejfv
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Enfortumab Vedotin-ejfv - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Enfortumab Vedotin-ejfv - Check for trials from NCI's list of cancer clinical trials now accepting patients.